Genetic Engineering In-Vitro In-Vivo RNA 
Drug Discovery World
JANUARY 23, 2023
Increasing interest in CRISPR-Cas gene editing systems over recent years has delivered innovative developments in precision genome engineering technologies, holding enormous potential for applications across the healthcare sector.
Drug Discovery World
MAY 10, 2023
Until recently, drug carcinogenicity assessment required two different in vivo studies, one of which was typically a two-year lifetime study in rats. Dr Megan MacBride and Dr Caroline Horizny Mitchell , Taconic, examine recent changes to animal testing in drug design. billion and take over 10 years.
Expert insights. Personalized for you.
52 
Let's personalize your content